Idalopirdine | CAS# 467459-31-0 | Biochemical

MedKoo Cat#: 576572 | Name: Idalopirdine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Idalopirdine is a potent and selective 5-HT6 receptor antagonist for potential use in the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.

Chemical Structure

Idalopirdine

CAS#467459-31-0 (free base)

Theoretical Analysis

MedKoo Cat#: 576572

Name: Idalopirdine

CAS#: 467459-31-0 (free base)

Chemical Formula: C20H19F5N2O

Exact Mass: 398.1418

Molecular Weight: 398.38

Elemental Analysis: C, 60.30; H, 4.81; F, 23.84; N, 7.03; O, 4.02

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 300.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

467459-31-0 (free base) 467458-02-2 (HCl)

Synonym

Idalopirdine; LU AE58054; LUAE58054; LU-AE58054

IUPAC/Chemical Name

2-(6-fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethan-1-amine

InChi Key

YBAWYTYNMZWMMJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2

SMILES Code

FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Idalopirdine (Lu AE58054) is a potent and selective 5-HT6 receptor antagonist with a Ki of 0.83 nM.

In vitro activity:

The binding of [3H]LSD to membranes from BHK cells expressing human 5-HT6Rs was inhibited in a concentration-dependent fashion by Lu AE58054. The affinity (Ki) of Lu AE58054 calculated for human 5-HT6Rs was 0.83 nM. The affinity of Lu AE58054 for 5-HT2ARs was 100-fold lower than for 5-HT6Rs and Lu AE58054 had over 400-fold lower affinity for the other 5-HTR subtypes examined (Table 1). Selectivity profiling in more than 80 binding as well as in 20 enzyme assays indicated >50 fold selectivity except for the adrenergic hα1A and hα1B receptors. Affinity and efficacy profiling for the hα1A and hα1B receptors demonstrated that Lu AE58054 displayed an affinity (Ki) of 21 and 22 nM, respectively, and inhibited epinephrine-induced activation of both receptors (Cerep Contract Facility and Lundbeck, data on file). Reference: Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. https://pubmed.ncbi.nlm.nih.gov/20569520/

In vivo activity:

The activity of idalopirdine was measured in the rat model of excessive eating. Animals were on a high caloric diet that consisted of milk chocolate with nuts, cheese, salted peanuts and condensed milk. During a four-week experiment, the rats had constant access to standard feed and water ad libitum. Idalopirdine was administered intraperitoneally at a dose 5 mg/kg b.w./day. To establish whether idalopirdine would effectively suppress the rebound hyperphagia that accompanies refeeding, it was administered after a 20 h food deprivation period. Pica behavior was evaluated after the administration of idalopirdine to confirm that the suppression of food intake was not caused by visceral illness. The effect of the four-week treatment with idalopirdine on the amount of peritoneal adipose tissue, and on lipid and carbohydrate profiles in rats was also examined. The statistical significance was calculated using the one-way ANOVA post-hoc Tukey Multiple Comparison Test or the two-way ANOVA post-hoc Bonferroni Multiple Comparison Test. Idalopirdine significantly reduced caloric intake and prevented the development of obesity in tested animals. Rats, that received idalopirdine, had a smaller amount of adipose tissue in the peritoneum as well as lower glucose, triglyceride and cholesterol levels in comparison to the control group. Moreover, an anorectic action was not caused by abnormalities of the gastrointestinal tract, such as nausea. The obtained results indicate that idalopirdine reduces caloric intake and could be considered for further tests as a potential treatment of obesity. Reference: Metab Brain Dis. 2018 Jun;33(3):733-740. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29297106/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	75.31
	DMSO	30.0	75.31
	Ethanol	30.0	75.31

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 398.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23. PMID: 20569520. 2. Kotańska M, Lustyk K, Bucki A, Marcinkowska M, Śniecikowska J, Kołaczkowski M. Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. Metab Brain Dis. 2018 Jun;33(3):733-740. doi: 10.1007/s11011-017-0175-1. Epub 2018 Jan 3. PMID: 29297106; PMCID: PMC5956042. 3. Dudek M, Marcinkowska M, Bucki A, Olczyk A, Kołaczkowski M. Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis. 2015 Dec;30(6):1487-94. doi: 10.1007/s11011-015-9736-3. Epub 2015 Sep 29. PMID: 26419385; PMCID: PMC4642593.

In vitro protocol:

In vivo protocol:

1. Kotańska M, Lustyk K, Bucki A, Marcinkowska M, Śniecikowska J, Kołaczkowski M. Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. Metab Brain Dis. 2018 Jun;33(3):733-740. doi: 10.1007/s11011-017-0175-1. Epub 2018 Jan 3. PMID: 29297106; PMCID: PMC5956042. 2. Dudek M, Marcinkowska M, Bucki A, Olczyk A, Kołaczkowski M. Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis. 2015 Dec;30(6):1487-94. doi: 10.1007/s11011-015-9736-3. Epub 2015 Sep 29. PMID: 26419385; PMCID: PMC4642593.

1. Arnt, J., Bang-Andersen, B., Grayson, B., et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 13(8), 1021-1033 (2010). 2. Cherian, A.K., Kucinski, A., Wu, R., et al. Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease. Psychopharmacology (Berl) 236(6), 1701-1715 (2019).